Introduction {#mjy052s1}
============

A complex system exists for maintaining human health that consists of dietary components, environmental chemicals, and pharmaceuticals that interact with genes for normal activity. Although there has been much research that has been performed regarding the various nutrients and metabolites required for health, considerably less focus has been placed on their transport in the body. This is partly because of technical challenges and the priority for noted genes. Thus, the identification of transporters has lagged behind other studies. Membrane transporters mainly include members of the ion and water channels, which are ATP-binding cassette (ABC) and solute carrier (SLC) transporters.

Current research has focused on the roles of SLC transporters in metabolic diseases. Human SLC transporter families contain 400 genes and 52 subfamilies. We describe a comprehensive similarity relationship of SLCs superfamily (Figure [1](#mjy052F1){ref-type="fig"}). SLCs contribute to the transmembrane transport of various substrates such as inorganic ions, amino acids, fatty acids, neurotransmitters, and saccharides. Many SLC susceptibility loci have been strongly associated with metabolic diseases including insulin resistance, type 2 diabetes mellitus (T2DM), elevated blood pressure, chronic kidney disease (CKD), gout, asthma, inflammatory bowel disease (IBD), cancer, dementia, and anxiety disorders (Table [1](#mjy052TB1){ref-type="table"}).

![The phylogenetic tree of SLC superfamily. Different colors represent different subfamilies (see [Supplementary Methods section](#sup1){ref-type="supplementary-material"}). The SLCs are mainly classified into six groups: (i) Group 1 includes the SLC8, SLC24, and SLC39 families; (ii) Group 2 includes the SLC6, SLC9, and SLC30 families; (iii) Group 3 includes the SLC2, SLC4, SLC22, SLC28, and SLC41 families; (iv) Group 4 includes the SLC16, SLC17, SLC18, SLC37, SLC43, SLC45, and SLC47 families; (v) Group 5 includes the SLC1, SLC25, SLC26, SLC27, SLC29, and SLC34 families; (vi) Group 6 includes the SLC5, SLC7, SLC10, SLC12, SLC13, SLC23, SLC35, SLC36, and SLC38 families. Subfamily similarities may imply common ancestry and suggest possible functional similarity.](mjy052f01){#mjy052F1}

###### 

Representative SLC transporter-relevant human diseases.

  SLC         Human diseases                                        Known substrates                                                                                      References
  ----------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  SLC2A2      T2DMinsulin resistance                                Facilitated glucose transporter                                                                       [@mjy052C30]
  SLC16A11    T2DM                                                  Transport of pyruvate across the plasma membrane                                                      [@mjy052C108]
  SLC30A8     T2DMInsulin resistance                                Zinc transporter 8                                                                                    [@mjy052C30]
  SLC6A1      Anxiety disorders                                     GABA transporter                                                                                      [@mjy052C125]
  SLC6A12     Schizophrenia in a Korean population                  GABA transporter                                                                                      [@mjy052C102]
  SLC6A15     Depression                                            Branched-chain amino acids, particularly leucine, valine, isoleucine, and methionine                  [@mjy052C52]
  SLC30A10    Neurologic, hepatic, and hematologic disturbances     Manganese transport                                                                                   [@mjy052C105]
  SLC24A4     Alzheimer's disease                                   Calcium transport                                                                                     [@mjy052C66]
  SLC2A9      Gout                                                  Urate                                                                                                 [@mjy052C28]; [@mjy052C63]
  SLC16A9     Gout                                                  Urate                                                                                                 [@mjy052C63]; [@mjy052C145]
  SLC17A1     Gout                                                  Sodium-dependent phosphate transporter 1; a renal transporter of uric acid                            [@mjy052C63]; [@mjy052C49]; [@mjy052C91]
  SLC17A3     Gout                                                  Urate                                                                                                 [@mjy052C28]
  SLC22A11    Gout                                                  Organic anion transporter 4                                                                           [@mjy052C145]; [@mjy052C34]
  SLC22A12    Gout                                                  Urate transporter 1                                                                                   [@mjy052C63]; [@mjy052C34]; [@mjy052C91]
  SLC4A7      Elevated blood pressure                               Electroneutral Na^+^/HCO~3~^−^ cotransporter NBCn1                                                    [@mjy052C76]; [@mjy052C31]; [@mjy052C132]; [@mjy052C93]
  SLC6A13     Elevated blood pressurechronic kidney disease (CKD)   GABA transporter                                                                                      [@mjy052C68]; [@mjy052C65]; [@mjy052C74]
  SLC8A1      Elevated blood pressure                               Sodium(Na^+^)-calcium(Ca^2+^) exchanger 1                                                             [@mjy052C133]
  SLC12A1     Blood pressure variation                              Kidney-specific sodium--potassium--chloride cotransporter; accounts for most of the NaCl resorption   [@mjy052C54]
  SLC12A3     Blood pressure variation                              Renal thiazide-sensitive sodium-chloride cotransporter                                                [@mjy052C54]
  SLC14A2     Elevated blood pressure                               Urea transporter                                                                                      [@mjy052C133]
  SLC22A4/5   Elevated blood pressure                               Gothioneine and carnitine                                                                             [@mjy052C131]
  SLC24A3     Elevated blood pressure                               K^+^-dependent Na^+^/Ca^2+^ exchanger 3                                                               [@mjy052C133]
  SLC35F1     Elevated blood pressure                               Unknown                                                                                               [@mjy052C133]
  SLC39A8     Elevated blood pressure                               Zinc transport                                                                                        [@mjy052C31]
  SLC39A13    Elevated blood pressure                               Zinc transport                                                                                        [@mjy052C31]
  SLC25A32    Blood pressure                                        Unknown                                                                                               [@mjy052C35]
  SLC7A9      CKD                                                   Transport of cystine and neutral and dibasic amino acids                                              [@mjy052C65]
  SLC34A1     CKD                                                   Sodium--phosphate cotransporter                                                                       [@mjy052C65]
  SLC22A2     CKD                                                   Metformin, cisplatin, and lamivudine                                                                  [@mjy052C65]; [@mjy052C74]
  SLC22A5     Asthma                                                Carnitine transporter                                                                                 [@mjy052C126]; [@mjy052C87]
  SLC30A8     Asthma                                                Zinc transporter 8                                                                                    [@mjy052C48]
  SLC22A23    Bronchodilator responsiveness in asthma               Unknown                                                                                               [@mjy052C97]
  SLC25A15    Bronchodilator responsiveness in asthma               Unknown                                                                                               [@mjy052C29]

For the human SLC family members, Table [1](#mjy052TB1){ref-type="table"} summarizes their types of predominant transport substrates and links to common diseases (T2DM, depression, Alzheimer's disease, gout, elevated blood pressure, CKD, and asthma).

The transmembrane transport by SLCs could be mainly divided into four modes of transport, including cotransporter, exchanger, facilitated transporter, and orphan transporter (Figure [2](#mjy052F2){ref-type="fig"}). Cotransporter is defined as the movement of one substrate via concentration gradient coupled with other components. The first discovered cotransporter was SLC5A1, which translocates Na^+^ and glucose in both directions across the epithelial cell membrane and thus provides glucose for glycolysis. Another Na^+^/glucose cotransporter for glucose reabsorption is SLC5A2, which mediates sodium uptake and glucose reabsorption in the proximal tubular cells ([@mjy052C40]). In the second class, exchanger is apparently referred to two substrates across the membrane in opposing direction. It was found that SLC9A3 mediates the translocation of Na^+^ and H^+^ in either direction across the membrane for preventing acidification in the gut. This mechanism is called the Na^+^/H^+^ exchanger. An additional important transporter in control of cell acidification is SLC16A1, which mediates the outward transport of lactate and H^+^ from glycolysis. In addition, citrate is exchanged with H^+^/malate on the inner mitochondrial membrane during the TCA cycle by SLC25A1. The third class is the facilitated transporter, which is considered as the spontaneous passive transport of one substrate without coupled components. For example, SLC25A8 facilitates the transfer of H^+^ from the inner to the outer mitochondrial membrane for energy metabolism. Another facilitating transporter is SLC19A3, which contributes to the intestinal absorption of thiamine uptake. Other complex transporters were called orphan transporter, and its substrates and consequent functions remain to be identified. The most recently found transporting mode is that of SLC38A9, which translocates leucine from the lysosome to the cytoplasm when mTORC1 binds to the lysosomal membrane. Besides, a series of drugs also can be transported by SLCs (Figure [2](#mjy052F2){ref-type="fig"}).

![Representative modes of SLC transport. SLCs constitute a dynamic work coordination for living cells. Different modes of SLC transport, including cotransporters, exchangers, facilitated and orphan transporters, are marked by different shapes and colors. The representative SLC transporters include SLC3A2/SLC7A5 (amino acids), SLC5A1 (glucose and Na^+^), SLC9A3 (Na^+^/H^+^ exchanger), SLC16A1 (lactate), SLC19A3 (thiamine), SLC25A1(citrate/malate exchanger), SLC25A8 (protons), SLC29A2 (nucleobases), SLC30A4 (Zn^2+^ to ER), SLC30A8 (Zn^2+^ to granules), SLC35A3 (UDP-GlcNAc to Golgi), SLC35A3 (UDP-galactose to ER), SLC38A9 (leucine), and SLC39A1 (Zn^2+^ to intracellular fluid). SLCs participate in important biological functions for glycolysis, acidification, TCA cycle, and nutrient supply. Among these, SLC3A2 and SLC7A5, considered as heteromeric amino acid transporters, are collaborative for amino acid transport. The activities of SLCs cover all organelles from nucleus to cell membrane.](mjy052f02){#mjy052F2}

Except for different modes, different organelles are also crucial for SLCs. For example, the SLC30A family mediates the transport of zinc in the nucleus (SLC30A9), endosome (SLC30A4), Golgi (SLC30A5, SLC30A6, SLC30A7), and secretory granules (SLC30A8) for alkaline phosphatases (ALPs). The SLCs are finely cooperative to regulate substrate movement. Moreover, SLCs regulate tissue-specific substrate movement associated with diseases (Figure [3](#mjy052F3){ref-type="fig"}A). Here, we review the characteristics and functional roles of various SLCs.

![(**A**) Tissues and diseases associated with SLCs. Major advances in understanding of the relationship between disease susceptibility and SLCs have been made. Accumulation of gene mutations and GWAS studies have demonstrated that SLCs play a crucial role in human diseases. SLCs are specifically expressed in different organs and involved in the pathogenesis of various human diseases. SLC members in the same family have been described that differ in the organ expression with different functions. The brain and kidney are two target organs for most high expression of SLCs-mediated diseases. Thus, SLCs are promising for neurologic and metabolic target. (**B**) SLC inhibitors for drug targets. The current SLC drug development is promising. Previous approved drugs were widely used for treatment of hyperglycemia, diuresis, movement disorders, uricosuresis, gout, and so on. Newly testing SLC drugs have the potential to exert antineoplastic effects, ameliorate Type 1 diabetes, resist constipation, protect from hypertension and schizophrenia. Data were cited from [@mjy052C107] and [@mjy052C15].](mjy052f03){#mjy052F3}

SLCs in human diseases {#mjy052s2}
======================

As the development of sequencing technology, the contributions of genetic variants to common diseases become more clear. To explore the functions of SLC transporters, the strong associations between SLCs and a variety of diseases are first established (summarized in Table [1](#mjy052TB1){ref-type="table"}).

SLCs for insulin resistance and T2DM {#mjy052s3}
------------------------------------

Obesity is a driver of complications such as insulin resistance and T2DM, which are considered to be a global burden ([@mjy052C151]). Although the etiology of T2DM is partially understood, new genetic loci continuously emerge. SLC2A2 was previously observed in a GWAS study for the loci of insulin resistance and T2DM ([@mjy052C30]). However, SLC2A2 is not the principal glucose transporter in human pancreatic β cells ([@mjy052C81]). SLC2A2, which also functions as the main liver glucose transporter, has been found to transport glucosamine at high affinity and other glucose and fructose molecules with lower affinity ([@mjy052C128]). It has been demonstrated that glucosamine inhibits β-cell glucokinase activity and reduces the insulin response ([@mjy052C147]). In addition, glucosamine can also induce endoplasmic reticulum (ER) stress in monocytes and hepatocytes involved in accelerating atherosclerosis in hyperglycemia ([@mjy052C135]).

SLC30A8, also known as zinc transporter 8 (ZnT8), is highly expressed in the pancreas that supports a potential role for affecting the endocrine system ([@mjy052C51]). A GWAS study revealed that SLC30A8 is another common SLC loci for T2DM, and its polymorphisms are linked to the T2DM susceptibility of various populations ([@mjy052C123]; [@mjy052C30]; [@mjy052C112]; [@mjy052C103]; [@mjy052C95]). Although ZnT8-null mice have a moderate glucose tolerance ([@mjy052C94]), glucose-stimulated insulin secretion was abolished in Slc30a7 and Slc30a8 double knockout mice ([@mjy052C122]). More recently, it was shown that selective deletion of ZnT8 in pancreatic β-cells induced a significant impairment in glucose tolerance, while ZnT8 overexpression in β-cells resulted in significant improvements in glucose tolerance ([@mjy052C83]). Interestingly, human Slc30a8 transgenic mice exhibited a decrease in pancreatic \[Zn^2+^\] concentration and higher insulin and glucose tolerance after consuming a high-fat diet ([@mjy052C69]).

It has been demonstrated that SLC16A11 is a locus associated with T2DM in the Mexico population ([@mjy052C115]; [@mjy052C82]). More recently, it was found that two distinct mechanisms of T2DM are a decrease in liver SLC16A11 expression and disruption of basigin (BSG) ([@mjy052C108]). However, the precise mechanisms of SLC16A11 leading to T2DM pathogenesis in humans remain unclear and further studies are required.

SLCs for elevated blood pressure {#mjy052s4}
--------------------------------

Elevated blood pressure continues to be a global public health problem, and it is also a major contributor to coronary heart disease ([@mjy052C8]). Thus far, over 200 genetic loci for blood pressure have been identified in GWAS studies, and the SLCs are involved including SLC4A7, SLC6A13, SLC8A1, SLC12A3, SLC25A32, SLC39A8, and SLC39A14 ([@mjy052C54]; [@mjy052C31]; [@mjy052C35]; [@mjy052C131]; [@mjy052C132]; [@mjy052C133]).

High sodium intake is one of the major risk factors for elevated blood pressure ([@mjy052C46]). Thus, Na^+^ transporters may play an important role in blood pressure variation. Recent evidence has revealed that SLC4A4 but not SLC4A7 was associated with dietary sodium intake-induced blood pressure responses in the Han Chinese population ([@mjy052C42]).

Generally, intracellular pH affects intracellular enzymatic activities and contributes to vascular function ([@mjy052C11]). The SLC4A7 gene is a Na^+^/HCO~3~^−^ transporter that mediates intracellular pH regulation in smooth muscle cells from the heart ([@mjy052C12]). Although SLC4A7-deficient mice displayed a lower pH in mesenteric artery smooth muscle and endothelial cells, they exhibited a modest hypertensive state ([@mjy052C10]). More recently, it was discovered that SLC4A7-deficient mice affect the migration of vascular smooth muscle cells and remodeling of carotid arteries that might be involved in the pathogenesis of occlusive artery disease ([@mjy052C93]).

SLCs for CKD {#mjy052s5}
------------

The incidence and prevalence of CKD are increasing worldwide. Previous GWAS studies have identified SLC6A13, SLC7A9, and SLC22A2 as susceptibility genes of CKD ([@mjy052C65]; [@mjy052C74]). SLC6A13, a GABA transporter, has been a susceptibility gene for both hypertension and CKD ([@mjy052C65]).

SLC22A2 belongs to the organic cation transporter (OCT) family ([@mjy052C38]). SLC22A2 mRNA is abundant in the kidney, especially the basolateral membrane of the proximal tubules, pointing to a role in the control of kidney uptake and nephrotoxicity ([@mjy052C55]). In early studies, SLC22A2 expression was significantly lowered in adenine-induced chronic renal failure rats ([@mjy052C96]). Moreover, cisplatin-induced kidney damage was abolished by SLC22A2 absence via p53 signaling ([@mjy052C118]). It is also evident that SLC22A2 polymorphisms were associated with reduced cisplatin-induced nephrotoxicity and maintenance of the estimated glomerular filtration rate in patients ([@mjy052C17]).

SLCs for gout {#mjy052s6}
-------------

Gout is characterized by chronic hyperuricemia and the formation of monosodium urate monohydrate crystals around joints ([@mjy052C71]). It is notable that uric acid transport seems to play a key role in the pathogenesis of gout. According to GWAS studies, SLCs including SLC2A9, SLC16A9, SLC17A1, SLC17A3, SLC22A11, and SLC22A12 were risk loci for gout ([@mjy052C28]; [@mjy052C63]; [@mjy052C34]). Because of different mechanisms, gout has been divided into renal overload gout and renal underexcretion gout. Human data showed that 30%--40% of urate is cleared in the intestine and most of the rest via the kidney ([@mjy052C116]). However, whether the uric acid concentrations in the gut and kidney are regulated by different SLCs is not clear.

SLC2A9, which is mainly expressed in the liver, kidney, and intestine (jejunum), is the most common cause of hyperuricemia ([@mjy052C27]). A previous study showed that SLC2A9 participates in the reabsorption of filtered urate by the proximal tubules. In SLC2A9 knockout mice, the animals exhibited a complex metabolic syndrome of hyperuricemia, hyperuricosuria, spontaneous hypertension, and dyslipidemia ([@mjy052C27]).

SLC16A9 also mediates urate transport. The physiological roles of SLC16A9 in gout are related to intestinal urate clearance rather than decreased renal urate excretion ([@mjy052C90]). There are no data in the literature describing SLC16A9 deficiency. SLC17A1, also called sodium phosphate transport protein 1 (NPT1), is expressed on the apical membrane of renal tubular cells and liver cells. SLC22A12 was also expressed on the apical side of the renal proximal tubule. SLC22A12 knockout mice exhibited a higher ratio of urinary urate/creatinine excretion, suggesting that SLC22A12 deficiency leads to reduced renal reabsorption of urate ([@mjy052C50]).

SLCs for neurological diseases and mental disorders {#mjy052s7}
---------------------------------------------------

There have been rising rates of anxiety that require lifetime medical care, which have driven increased concerns ([@mjy052C2]). GWAS studies have implicated SLC3A1 and SLC6A15 in association with the increased risk of anxiety disorders and major depression (MD), respectively ([@mjy052C62]; [@mjy052C26]; [@mjy052C39]; [@mjy052C100]). SLC3A1 and SLC6A15 are amino acid transporters, and their substrate transport mechanisms remain unclear. A further attempt in animal revealed that SLC3A1 deficiency causes cystinuria, and its relation to anxiety requires further research ([@mjy052C110]; [@mjy052C85]). Consistent with human data, SLC6A15 knockout mice exhibited less anxiety- and depressive-like behavior in response to chronic social stress compared to wild-type mice, while SLC6A15 overexpression mice possessed increased anxiety-like behavior ([@mjy052C109]).

Alzheimer's disease (AD) with progressive cognitive deterioration has quickly become widespread that affects everyday activities ([@mjy052C1]). A GWAS meta-analysis determined that SLC24A4 was a susceptibility loci of AD ([@mjy052C66]). SLC24A4, highly expressed in the brain and olfactory neurons, exchanged four Na^+^ for one Ca^2+^ and one K^+^ across the cell membrane via an electrochemical gradient ([@mjy052C111]). In animals, SLC24A4 deficiency displayed stronger olfactory neuronal adaptation and a prolonged termination phase in olfactory response ([@mjy052C120]). Interestingly, SLC24A4 loss has no influence on the response sensitivity of odorant exposure in mice, indicating that other components in the complex olfactory system regulate sensory stimuli. More recently, it was demonstrated that olfactory action was altered by a loss of both SLC24A4 and CNGB1 in mice, which displayed markedly reduced EOG amplitude and change of resting sensitivity ([@mjy052C32]).

SLCs in immunological dysfunction {#mjy052s8}
---------------------------------

Asthma, characterized by airway lymphocyte infiltration and inflammation, is the most common chronic T helper (Th) type 2-related immunological childhood disorder ([@mjy052C13]). The prevalence of allergies and asthma is continuously increasing, particularly in developed countries ([@mjy052C6]). Two large-scale GWAS for asthma found that SLC22A5 and SLC30A8 were significantly associated with asthma ([@mjy052C87]; [@mjy052C97]). It has been confirmed that prednisolone (a drug commonly for asthma) with L-carnitine ester stimulate prednisolone absorption across the bronchial epithelial cells via a SLC22A5 mechanism ([@mjy052C86]). Moreover, it has been demonstrated that SLC22A23 and SLC25A15 are strongly associated with the bronchodilator responsiveness of asthma ([@mjy052C48]; [@mjy052C29]).

IBD, including Crohn's disease and ulcerative colitis, also display an immunological dysfunction ([@mjy052C140]). SLC transporters identified in current GWAS of IBD contain SLC2A4, SLC9A3, SLC9A4, SLC11A1, SLC22A4, SLC22A5, SLC25A15, SLC26A3, SLC30A8, SLC22A23, and SLC39A8 ([@mjy052C60]; [@mjy052C142]; [@mjy052C75]). This suggests that glucose, iron, zinc, carnitine, chloride ion, and the transport of other unknown substrates are involved in complex mechanisms of IBD. The function of several functional genes has been successfully identified in an animal model. For example, Slc22a5-deficient mice develop spontaneous intestinal ulcers and perforation with intense lymphocytic and macrophage infiltration ([@mjy052C113]).

SLCs in cancer {#mjy052s9}
--------------

Butyrate is a tumor suppressor that acted as a histone deacetylase inhibitor ([@mjy052C24]). SLC5A8 may contribute to tumor progression because its one important transport substrate is butyrate ([@mjy052C43]). Moreover, SLC5A8 also participated in colonic lactate transport, and Slc5a8-deficient mice displayed lactaturia ([@mjy052C36]). There is decreased expression of SLC5A8 in most tumors due to the loss of lactate transport, which is a feature of the Warburg effect ([@mjy052C130]). The Warburg effect requires an increased glucose uptake for cancer cells, which aggravates the expression of glucose transporter SLC2A1 ([@mjy052C114]). Unlike SLC5A8, SLC2A1 is highly expressed in most tumors.

GWAS analysis demonstrated that variants of SLC8A1 were closely related to the risk of colorectal neoplasia and calcium intake and inversely correlated with colorectal adenomas ([@mjy052C150]). SLC8A1 functions as a Na^+^/Ca^2+^ exchanger and mediates the extrusion of Ca^2+^ ion across the cell membrane ([@mjy052C59]). Ca^2+^ signals from SLC8A1 participate in immunology and are required for inflammatory TNF-α production in intestine ([@mjy052C119]). More importantly, SLC8A1 is essential for PKC-α activation, which further participates in ERK1/2 phosphorylation in endothelial cells ([@mjy052C5]). Thus, tumor angiogenesis may be regulated by SLC8A1 expression.

There are some SLCs linked to cancer risk, although the substrates or mechanisms remain unclear. SLC39A6 has been associated with esophageal cancer suppression, and a GWAS showed that it may contribute to longer survival ([@mjy052C138]). Another GWAS has identified SLC13A2 as a risk factor for familial HBV-related hepatocellular carcinoma ([@mjy052C72]).

SLCs in nutrient and metabolite sensing and regulation {#mjy052s10}
======================================================

In recent years, a great deal of GWAS of complex diseases have been published, and various risk loci have been successfully identified. However, the progress of exploring identified functional genes related to diseases has been relatively slow. Many of these loci were later required to be functionally confirmed by global or tissue-specific gene knockout experiments in mice (summarized in Table [2](#mjy052TB2){ref-type="table"}). Table 2Animal model phenotypes relative to representative Slc transporters.SlcDiseases/defectsAnimal modelsReferencesSlc2a4Fasting hyperglycemia and glucose intoleranceGlobal Slc2a4-deficient mice[@mjy052C58]Slc2a4Glucose uptake reduced by 75%Muscle-specific Glut4 knockout (KO) mice[@mjy052C152]Slc2a4Insulin resistance secondarily in muscle and liverAdipose-specific Glut4 KO mice[@mjy052C143]Slc2a4Impaired ability in mouse under stressCardiac-specific Glut4 KO mice[@mjy052C134]Slc2a4Protection from albuminuria and diabetic nephropathyPodocyte-specific Glut4 KO mice[@mjy052C44]Slc2a9Hyperuricaemia, hyperuricosuria, spontaneous hypertension, dyslipidemia, and elevated body fatGlut9 KO mice[@mjy052C27]Slc3a1CystinuriaSlc3a1 KO Feline[@mjy052C85]Slc5a2Prevention from HFD-induced hyperglycemia and glucose intolerance; reduced plasma insulin concentrationsSlc5a2 KO mice[@mjy052C57]Slc6a15Less anxiety- and depressive-like behaviorSlc6a15 KO mice[@mjy052C109]Slc6a15Increased anxiety-like behaviorSlc6a15 overexpression mice[@mjy052C109]Slc11a1Sensitive to *Salmonella typhimurium* infectionSlc11a1 KO mice[@mjy052C14]Slc12a1Decreased neuronal layer thickness and cell number; more immature interneuronsSlc12a1 KO mice[@mjy052C45]; [@mjy052C77]Slc13a1HyposulfatemiaNaS1-null (Nas1^−/−^) mice[@mjy052C80]Slc15a1Higher plasma amino acid levelsSlc15a1 KO mice[@mjy052C144]Slc15a2Lower body weight and lower relative heart weight in male PEPT2-null mice; lower relative kidney weight in female micePEPT2-null mice[@mjy052C37]Slc16a1HyperinsulinismRIP7-rtTA/Mct1-Luc mice[@mjy052C104]Slc17a1Normal plasma Pi and calcium levels; reduced Pi excretionNPT1^−/−^ mice[@mjy052C84]Slc19a3Neurodegenerative disorderSlc19a3-deficient mice[@mjy052C121]Slc20a2Dysregulated phosphate homeostasis basal ganglia calcificationHeterzygous (Het) Slc20a2 mice[@mjy052C153]Slc23a1Lower plasma ascorbate concentrations; brain hemorrhageSlc23a1 KO mice[@mjy052C117]Slc24a4A deficit in olfactory neuronsSlc24a4 KO mice[@mjy052C70]Slc26a1Hyposulfatemia, hyperoxalemia; transport anions including sulfate, bicarbonate, chloride, and oxalateSat1-null (Sat1^−/−^)/Sat1 KO mice[@mjy052C79]Slc27a1Reduced insulin resistance; decreased electroretinogram responseSlc27a1 KO mice[@mjy052C61]; [@mjy052C18]Slc30a8Islets with markedly fewer dense cores but more rod-like crystalsZnT8-null (Slc30a8^−/−^) mice[@mjy052C94]Slc38a3Stunted growth, altered amino acid levels, hypoglycemia, and 20-day life; higher glutamine but reduced glutamate and γ-aminobutyric acid (GABA) levels in brain; reduced renal ammonium excretionSnat3 mutant mice; Snat3-deficient mice[@mjy052C16]Slc39a14Impairs hepatic Mn uptake and biliary excretion, resulting in the accumulation of Mn in the circulation and brainGlobal Slc39a14 KO mice;hepatocyte-specific Slc39a14 KO mice[@mjy052C141][^2]

Amino acids, glucose, and lipids---major nutrients {#mjy052s11}
--------------------------------------------------

Dietary carbohydrate is necessary for supplying humans with essential saccharides and energy. SLC2A4 (GLUT4) has well-established roles as a glucose transporter affecting the body glucose disposal rate in adipose, muscle, and cardiac tissues ([@mjy052C88]). SLC2A4 global-deficient mice exhibited fasting hyperglycemia and glucose intolerance, while overexpression of SLC2A4 in adipose tissue resulted in alleviating insulin resistance ([@mjy052C143]). In a tissue-specific model, the muscle in mice lacking SLC2A4 displayed a loss of glucose uptake compared to wild-type, and cardiac deletion of SLC2A4 resulted in an impaired ability in stressed mice ([@mjy052C152]; [@mjy052C134]). In recent years, it was found that podocyte-specific GLUT4-deficient mice did not develop albuminuria and diabetic nephropathy ([@mjy052C44]). These results indicated that the main target tissues of SLC2A4 are adipose and muscle for metabolic disease.

Dietary proteins and their amino acid products are essential for the maintenance of human nutrition and development. SLC15A1 regulates the absorption and homeostasis of most amino acids in the intestine ([@mjy052C22]). Furthermore, almost all the plasma amino acid levels of SLC15A1-deficient mice were significantly increased compared to wild-type ([@mjy052C92]). Interestingly, the intestinal amino acid absorption regulated by SLC15A1 is notable only after high dietary protein intake ([@mjy052C92]). Considering all these, SLC15A1 has contributed to amino acids absorption from intestine and transport from circulation to whole body. SLC15A2, mainly expressed in the kidney, prevents the urinary loss of amino acids and assists with meeting the nutritional needs of the body by renal reabsorption of these amino acids and peptides ([@mjy052C92]). Furthermore, SLC15A2^−/−^ animals possessed lower body weight and relative heart weight compared with wild-type animals, suggesting a loss of amino acids in the heart ([@mjy052C37]). SLC15A2 controls amino acids transport from tissue to circulation which differs from SLC15A1.

Glutamine, mainly transported by SLC38A3, is the most abundant amino acid in the body and is involved in various processes ([@mjy052C21]). SLC38A3 expression linked with tissue development is demonstrated by short life of SLC38A3 mutant mice with hypoglycemia, suggesting that glutamine transport is crucial for growth and development ([@mjy052C16]). Additionally, the urea levels and renal ammonium excretion were decreased in SLC38A3-deficient mice ([@mjy052C16]). To sum up, SLC38A3 influences the glutamine accumulation in tissues and interacts with other amino acids.

MTORC1, an important amino acid-sensing molecule that regulates cell growth, has been considered as a key cancer signaling pathway ([@mjy052C41]). SLC38A9 has been recently demonstrated to transport amino acids and regulate the downstream of mTORC1 signaling in lysosomes, which provides higher levels of amino acids for the cell ([@mjy052C139]). Arginine is one of the elusive sensors for the mTORC1 pathway. SLC38A9 exhibits low amino acid-sensing activity for arginine transport, which suppresses mTORC1 activity ([@mjy052C136]). As a high-affinity transporter for leucine, the amino acid preference of SLC38A9 is leucine. In an animal feeding study, the Slc38a9 expression in the hypothalamus of the brain was upregulated by a high-fat diet, suggesting that Slc38a9 has an impact on eating behavior ([@mjy052C47]). It is predicted that SLC38A9 may regulate cancer signaling and eating behavior via leucine.

As a major nutrient, fatty acids play an important physiological role in the regulation of body weight, energy metabolism, insulin sensitivity, cell-surface receptors, and brain development ([@mjy052C23]). The accumulation of lipids and the transport of fatty acids among tissues lead to various obesity-related metabolic diseases.

SLC27A1, one of the fatty acid transport proteins, is highly expressed in skeletal muscle, heart, and adipose tissue for long-chain fatty acid uptake ([@mjy052C4]). SLC27A1 deficiency has a limited impact on the alleviation of whole-body adiposity, but protects high-fat-fed mice from insulin resistance ([@mjy052C61]). SLC27A1 has been implicated in significantly reducing large cardiac lesion areas in Ldlr^−/−^ mice ([@mjy052C148]). Moreover, SLC27A1 knockout mice displayed a decrease in the neuroretina and response to light, leading to an aging process ([@mjy052C18]). In addition, SLC27A1 was recently found to enhance the transport of docosahexaenoic acid (DHA) into the brain via the membrane of brain microvessel endothelial cells ([@mjy052C98]). Considering all these, SLC27A1 may confer an anti-inflammation role in tissues which influence the process of inflammation-induced injury or aging.

Vitamins, metallic trace elements---trace nutrients {#mjy052s12}
---------------------------------------------------

Ascorbic acid (vitamin C) is essential for its antioxidant role in the body ([@mjy052C101]). A deficiency of SLC23A1 in mice causes respiratory failure and intracerebral hemorrhage in newborn mice, implying that SLC23A1 is essential for lung alveolar expansion and blood vessel development in the brain ([@mjy052C101]). Human polymorphisms in SLC23A1 have also been associated with aggressive periodontitis and Crohn's disease ([@mjy052C3]; [@mjy052C25]). These results have proved that SLC23A1 has a deep impact on tissue development beyond antioxidant vitamin C uptake.

Vitamin B1, mediated by Slc19a3 transport, is an important nutrient for energy production, and its deficiency has been linked to cardiac failure, neurological disorders, and oxidative stress ([@mjy052C19]). In Slc19a3-deficient mice, the animals displayed a neurodegenerative disorder, and a high dose of thiamine intake alleviated neurodegeneration ([@mjy052C121]). Neurological damage also was demonstrated in humans with inherited thiamine defects ([@mjy052C99]). Thus, SLC19A3 is mainly contributed to brain thiamine transport.

Iron is a crucial cofactor for important biological processes including cellular survival, cell death, respiration reduction reaction, and transport of oxygen via hemoglobin ([@mjy052C67]). SLC11A1 has been shown to transport iron. The SLC11A1 knockout or transgenic model is highly susceptible to diarrhea and colitis caused by *Salmonella* infection by inducing an inflammatory response and macrophage recruitment. Thus, SLC11A1 plays a critical role in host defense against infectious *Salmonella* ([@mjy052C137]; [@mjy052C129]).

SLC39A8 (ZIP8) contributes to the uptake of zinc into host cells, thereby providing the competitive advantage of zinc influx. SLC39A8 hypomorphic mice exhibited dysregulated zinc uptake and increased NF-κB activation ([@mjy052C73]). The mechanism of SLC39A8 in the host defense that negatively regulates NF-κB through IKK-β signaling might potentially protect against infection.

SLC11A1, SLC39A8, and SLC30A10 were not only implicated in iron or zinc transport but they also influenced Mn distribution in the body ([@mjy052C127]). Moreover, it was found that global loss of the Slc39a14 gene increases brain Mn accumulation, leading to motor deficits in the mouse ([@mjy052C141]). Additionally, it was found that Slc39a14 liver-specific-deficient mice had no motor deficits due to no increase in Mn levels in brain tissues, indicating that liver Slc39a14 expression has no effect on whole-body Mn homeostasis. To sum up, Mn transport is influenced by other metal ions transporters and Slc39a14 is the main transporter in brain.

Metabolite transport and interaction with microbiota {#mjy052s13}
----------------------------------------------------

Despite the presence of nutrients, many metabolites are also transported or influenced by SLCs. Intestinal serotonin, produced by tryptophan metabolism from enterochromaffin cells, is implicated in stimulating the nervous system and GI function ([@mjy052C9]). SLC6A4, the main serotonin transporter in the intestine, was influenced by gut microbiota composition ([@mjy052C9]). The germ-free mice displayed increased colonic SLC6A4 expression and reduced serotonin levels compared to normal commensal microbiota mice. Furthermore, SLC6A4 knockout mice exhibited decreased gut serotonin levels, indicating that a serotonin-deficient compensatory response regulated by SLC6A4 relied on the microbiota ([@mjy052C146]). Thus, SLC6A4 regulates serotonin distribution via brain--gut axis.

Dietary fiber also contributes to human health, and low fiber intake is associated with obesity-related metabolic disease ([@mjy052C33]). An important mechanism involved is that short-chain fatty acids, produced by the intestinal fermentation of dietary fiber, can modulate the microbiota, reduce the appetite, and protect against chronic inflammation ([@mjy052C20]). SLC16A1, which is a butyric acid transporter, maintains luminal butyrate levels and thus provides fuel for mucosal cells ([@mjy052C56]). In contrast, SLC16A1 expression was downregulated in inflammatory tissues with lower butyric acid levels in the gut ([@mjy052C124]). Moreover, β-cell-specific SLC16A1 overexpression in transgenic mice exhibited decreased fasting blood glucose levels ([@mjy052C104]). It is concluded that gut and pancreatic butyric acid transport mediated by SLC16A1 to reduce chronic inflammation.

SLCs for drug targets {#mjy052s14}
=====================

There has been increased interest in the targets of SLCs for drug development. A review of molecular drug targets found that 12 SLCs out of 435 human genes could be used as drug targets ([@mjy052C106]). Because most SLCs contribute to the transport of small organic molecules, it is predicted that the drug development of SLCs will be promising.

There are seven classes of SLCs that have been approved for market and nine classes of SLC drugs in clinical trials (Figure [3](#mjy052F3){ref-type="fig"}B and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) according to two reviews of previous research ([@mjy052C107]; [@mjy052C15]). These drug targets are linked to a wide variety of diseases such as hyperglycemia, depression, addiction, uricosuria, gout, and cancer. Among these drug targets, the SLC5 and SLC6 classes have been the most intensively studied targets. Dapagliflozin, the most well-known SGLT2 (sodium-glucose cotransporter 2 or SLC5A2) inhibitor, has been reported to attenuate blood glucose concentration in an insulin-independent manner. Clinical trials revealed that dapagliflozin safely reduced hyperglycemia without electrolyte disturbances, hepatotoxicity, or nephrotoxicity ([@mjy052C89]). Fluoxetine, the most utilized SLC6A4 inhibitor, could benefit adolescents with major depressive disorder by decreasing suicidal thinking ([@mjy052C78]).

Another important drug target for neurological disorders is the SLC class. NKCC1 has a favorable chloride transport capacity to accumulate intracellular Cl^−^ levels in immature neurons and interact with K^+^--Cl^−^ cotransporter (KCC, SLC12A5) ([@mjy052C53]). An NKCC1 deficiency results in a reduction of immature interneuron migration and a decrease of \~20% of the neuronal layer thickness, suggesting that NKCC1 contributes to the dynamic equilibrium of neurogenesis in mice ([@mjy052C45]; [@mjy052C77]). Selective NKCC1 inhibitors known as diuretics including bumetanide and furosemide improve neurological behavior control and lower anxiety, neuropathic pain, and schizophrenia in animals and patients ([@mjy052C7]).

Perspective {#mjy052s15}
===========

Compared to other gene families, SLCs are not well established, which is why this field is promising. In recent years, CRISPER/Cas9 has been a gene editing tool with high efficiency, and a great number of SLC knockout animal models were constructed for screening risk loci and drug targets of diseases. Moreover, there also remains a great need for two or more SLC gene knockout animals to uncover the interaction of SLCs, especially those that share the same transporting substrates.

We still face challenges in understanding the SLC contribution to human health. It is very likely that a large number of substrates for SLCs have not yet been identified, and the major substrates are also unknown. An important fact is that many SLC risk loci of human diseases have not been verified in gene-deficient animal models. This has occurred partly because of different tissue expression of target genes in different mammalian species. Other interesting fields may involve different diseases that share the same SLC risk loci. For example, SLC22A23 is not only a locus for Crohn's disease but also a risk gene for bronchodilator responsiveness in asthma (Table [1](#mjy052TB1){ref-type="table"}). Another SLC6A13 locus contributes to both elevated blood pressure and CKD (Table [1](#mjy052TB1){ref-type="table"}). Thus, the exploration of SLCs may give insight into complex human diseases.

SLC transporters have aroused the attention of the pharmaceutical industry. Most recently, Jnana Therapeutics Inc., the first medical company focusing on SLC transporters, was established in Boston, MA, USA and received \$50 million Series A financing (<https://www.jnanatx.com/>). The aim of this company is to explore the mechanism of SLC-associated immunometabolism, lysosomal function, and mucosal defense and develop drugs for immuno-oncology, inflammatory disorders, and neurological diseases.

In conclusion, a global understanding of SLC transporters will guide novel nutritional strategies, promote metabolic assessment, and facilitate drug development.
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